Merck & Co
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1891-01-01
- Employees
- 72K
- Market Cap
- -
- Website
- http://www.merck.com
- Introduction
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Clinical Trials
266
Trial Phases
2 Phases
Drug Approvals
5
Drug Approvals
Haemophilus b Conjugate Vaccine(Meningococcal Protein Conjugate)
- Product Name
- 普泽欣
- Approval Number
- S20040078
- Approval Date
- Dec 27, 2004
Hepatitis A Vaccine Purified Inactivated
- Product Name
- 维康特
- Approval Number
- S20040041
- Approval Date
- Jul 23, 2004
Hepatitis A Vaccine Purified Inactivated
- Product Name
- 维康特
- Approval Number
- S20040040
- Approval Date
- Jul 23, 2004
Clinical Trials
Distribution across different clinical trial phases (115 trials with phase data)• Click on a phase to view related trials
News
Sino Biopharm Acquires LaNova Medicines for $950M, Expanding Innovative Drug Pipeline
Sino Biopharm announced acquisition of remaining 95.09% stake in LaNova Medicines for up to $950 million, making it a wholly owned subsidiary.
FDA Approves First Year-Long Flea and Tick Injectable for Dogs
The FDA has approved BRAVECTO QUANTUM, the first and only parasiticide that protects dogs against fleas and ticks for an entire year with a single injection.
BioInvent's BI-1206 Shows Promising Phase 1 Results in Combination with Pembrolizumab for Solid Tumors
BioInvent's Phase 1 study of BI-1206 combined with pembrolizumab demonstrated encouraging clinical activity in heavily pre-treated solid tumor patients, with one complete response and one partial response among 36 evaluable patients.
Microbiotica Reveals Novel Mechanisms of Microbiome-Enhanced Immunotherapy Response with MB097
Microbiotica presented new preclinical data at the AACR annual meeting showing how MB097's bacterial strains enhance immune checkpoint inhibitor response through multiple mechanisms.